A phase II study of @entity1206 , XXXX and @entity900 chemotherapy for advanced @entity1149 .

@entity1 @entity137 @entity390 @entity882 @entity1138 @entity900 @entity1149 @entity1206 @entity1431
BACKGROUND: This prospective phase II trial was performed to determine the efficacy and @entity137 of @entity1138 , @entity1206 and @entity900 combination chemotherapy for @entity1 with previously untreated stage IIIB or IV @entity1149 ( @entity1149 ). METHODS: Between January 1999 and April 2001, 30 @entity1 with chemotherapy-naive stage IIIB or IV @entity1149 were entered into this study. @entity1138 at a dose of 7 mg/m2, @entity1206 at a dose of 25 mg/m2 and @entity900 at a dose of 75 mg/m2 on day 1 and @entity1206 at a dose of 25 mg/m2 on day 8 were administered. This regimen was repeated every 4 weeks. RESULTS: 29 @entity1 out of 30 @entity1 were assessable. Among the assessable @entity1 , 15 (51.7%) @entity1 had a partial response. The median duration of response and survival was 22 weeks and 39 weeks, respectively. Grade 3 or 4 @entity1431 and @entity882 were observed in 28.3% and 4.7% of all the cycles, respectively. @entity390 and vomiting of grade 3 occurred only in 2.4% of all the cycles. CONCLUSION: The regimen of @entity1138 , @entity1206 and @entity900 for @entity1149 is active against advanced @entity1149 with tolerable @entity137 .
